Skip to content
Zoom Webinar
  • September 30, 2021 from 12:00pm to 1:00pm

Attend the next CanPath webinar on Sept. 30 to learn how CanPath cohort data is used by the CAN-AIM team to research drug safety and effectiveness concerns in Canada. This webinar will be presented by Dr. Sasha Bernatsky and Dr. Cristiano Moura, investigators at CAN-AIM.

Adverse drug events will cost the Canadian healthcare system about $18 billion in the coming year and cause over 22,000 deaths. The Canadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM) responds to drug safety and effectiveness concerns from Health Canada and other regulators. To do so, CAN-AIM depends upon real-world cohort data, including CanPath.

Already, CanPath data have been used by CAN-AIM to study hypertension, diabetes, and other important topics. In this webinar, the CAN-AIM team will illustrate the use of linked drug dispensation records to derive information on the longitudinal use in Canada of H2 blockers, particularly ranitidine, a drug with recently emerging safety concerns.